Briefing Book

Investigational Medicinal Product

January 2020

**Contents**

[I. General information 3](#_Toc32754987)

[I-1. General data concerning the therapeutic indication 3](#_Toc32754988)

[I-2. General data concerning the product under development 3](#_Toc32754989)

[I-3. Regulatory status 3](#_Toc32754990)

[II. Quality 4](#_Toc32754991)

[II-1. Product composition 4](#_Toc32754992)

[II-2. Active substance 4](#_Toc32754993)

[II-3. Finished product 5](#_Toc32754994)

[II-4. Product sterilisation 5](#_Toc32754995)

[Select an item 5](#_Toc32754996)

[III. Non-clinical development status 5](#_Toc32754997)

[III-1. Pharmacology 5](#_Toc32754998)

[III-2. Pharmacokinetics (in relevant species) 6](#_Toc32754999)

[III-3. Toxicology 6](#_Toc32755000)

[III-4. Selection of doses (if First In Man) 6](#_Toc32755001)

[IV. Clinical development status 7](#_Toc32755002)

[IV-1. Completed and ongoing clinical trials 7](#_Toc32755003)

[IV-2. Synoptic tables of completed and ongoing clinical trials 7](#_Toc32755004)

[V. Scheduled clinical development 8](#_Toc32755005)

[V-1. Synoptic tables of scheduled clinical trials 8](#_Toc32755006)

[V-2. Conditions of Study “XXX” *(Systematically if Application for clinical trial authorisation, only if relevant for Request for scientific advice); (In the event of several studies, complete another section V-3):* 8](#_Toc32755007)

[VI. Rationale for request for scientific advice (only for a request for scientific advice) 8](#_Toc32755008)

[VII. Questions – Responses 9](#_Toc32755009)

1. General information

I-1. General data concerning the therapeutic indication

|  |  |  |
| --- | --- | --- |
| a | Therapeutic indication claimed and general data concerning the disease |  |
| **b** | Unmet medical need  Description of current treatments and Standard of care | Yes  No |

I-2. General data concerning the product under development

|  |  |  |
| --- | --- | --- |
| a | Product status (Chemical medicinal product, Biological medicinal product, ATMP, combined ATMP),  Composition and pharmacotherapeutic class and biological activity/activities |  |
| b | Mechanism of action envisaged in the claimed indication  Degree of innovation (new mechanism of action, new entity) and justification of capacity to meet a potential unmet medical need |  |
| d | Dose, frequency and route of administration envisaged  (as monotherapy or in combination) |  |

I-3. Regulatory status

|  |  |  |
| --- | --- | --- |
| a | Regulatory status (*specify*): | Orphan drug designation in the EU (date and procedure No.)  PIP (submission or validation date, procedure No.)  Select an item  MA if yes, specify   * date and * if in Europe, specify the procedure, the country for a national procedure and the RMS and countries concerned for a mutual recognition/decentralised procedure * if in another part of the world (specify)   Scientific advice already provided; if yes, specify   * the date(s) * if national with the list of countries (in Europe or outside Europe) * if European   PRIME application envisaged  Other, specify |
| b | Guidelines to which the applicant referred in its development |  |

1. Quality

II-1. Product composition

|  |  |
| --- | --- |
| Molecule structure: |  |

II-2. Active substance

|  |  |  |
| --- | --- | --- |
| Is there a monograph for the active substance? | Yes  No | If yes, specify:  Ph. Eur.  Pharmacopoeia of an EU member country  USP/JP |
| Does the active substance of a medicinal product authorised in the EU made by another manufacturer use the same process? | Yes  No | If yes, please indicate the authorised medicinal product: |
| Has the active substance described in an ASMF\* already been submitted to the ANSM and accepted in support of a given pharmaceutical product? | Yes  No | If yes, indicate the ASMF number or the CEP number: |
| **Control of starting materials:**  Are there any materials of animal or human origin used in the process | Yes  No |  |
| **Qualification of impurities**  Have the impurities been qualified in non-clinical studies | Yes  No |  |

II-3. Finished product

|  |  |  |
| --- | --- | --- |
| Excipients | Are any non-European Pharmacopoeia excipients used in the formulation? | Yes   No NA |
| Are any novel excipients used in the formulation? | Yes   No NA |
| Are there any excipients of animal or human origin? | Yes   No NA |
| Is the BSE/TSE risk documented? | Yes   No NA |
| Dosing device | Presence of a dosing or administration device?  If yes, describe the device:    Is it CE marked?  Have ongoing stability studies been conducted? | Yes   No  Yes   No  Yes   No |

II-4. Product sterilisation

|  |  |
| --- | --- |
| Is the product sterile | Yes   No |
| If yes, specify the type of sterilisation | Select an item |
| II-3 Pharmaceutical development status | |
| Formulations developed to date  Other formulations envisaged  Studies conducted  Studies envisaged |  |

1. Non-clinical development status

Synoptic Tables of key studies and results and/or related to the request for scientific advice, details in the Investigator’s Brochure.

III-1. Pharmacology

|  |  |  |  |
| --- | --- | --- | --- |
| a | **Primary pharmacology:**  In vivo / in vitro studies performed (Mechanism of action, proof of concept, justification of animal models, etc.): | |  |
| b | **Secondary pharmacology:**  Screening of other restrictive targets (“off-target”): | |  |
| c | Safety | Cardiovascular: | Yes   No NA |
| Central nervous system: | Yes   No NA |
| Respiratory system: | Yes   No NA |
| Other (renal, etc.): | Yes   No NA |

III-2. Pharmacokinetics (in relevant species)

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Species |  | | | | | | |
| Dose |  | | | | | | |
| Route of administration | | Bioavailability | AUC (ng.h.ml) | Cmax (ng/ml) | Tmax (h) | T1/2 | Vd |
|  | |  |  |  |  |  |  |
| **Describe elimination** | |  | | | | | |

III-3. Toxicology

|  |  |  |
| --- | --- | --- |
| a | Non-clinical single-dose toxicity studies (species used, dose and route of administration of the investigational medicinal product, lethal dose, observed toxicities) | |
| b | Non-clinical repeated-dose toxicity studies (species used, dose, route and duration of administration of the investigational medicinal product, NOEL and NOAEL, exposure, observed toxicities) | |
| c | Is the product genotoxic? | Yes   No NA/ Studies not performed (comment) |
| d | Reprotoxicity studies performed?  If yes, synoptic table of studies/species/age/doses  If yes, specify whether the product is reprotoxic | Yes   No NA |
| e | Is the product phototoxic | Yes   No NA/ Studies not performed (comment) |
| f | Have juvenile toxicity studies been performed?  If yes, synoptic table of studies/species/age/doses | Yes   No NA/ Studies not performed (comment) |

III-4. Selection of doses (if First In Man)

|  |  |  |
| --- | --- | --- |
| a | Starting dose: non-clinical criteria used for selection of the 1st dose | Select an item |
| What approach was used for the scale? | Select an item  Specify |
| d | Safety margin | Describe the safety margins (AUC and Cmax) as well as the calculation methods |

1. Clinical development status

IV-1. Completed and ongoing clinical trials

|  |  |  |
| --- | --- | --- |
| a | Number of clinical trials  (completed or ongoing) |  |
| b | Total number of patients included in these trials and in France |  |

IV-2. Synoptic tables of completed and ongoing clinical trials

|  |  |  |
| --- | --- | --- |
| a | Study title (and Eudract No.) and study phase |  |
| b | Study objective(s) | * Primary * Secondary |
| c | Study design | In particular, specify whether randomised or non-randomised, open-label or single or double-blind, comparative or non-comparative, parallel groups or otherwise, number of arms, if add-on or not, etc. |
| d | Study population | Total number of subjects  Healthy volunteers or patients (disease)  Main inclusion and exclusion criteria (indication) |
| e | Product(s) tested |  |
| f | Product dosage tested | Detail per arm: dose, frequency and route of administration, number of patients |
| g | Outcome measures | Primary outcome measure(s)  Secondary outcome measure(s)  Exploratory outcome measure(s) |
| h | Main efficacy results | On primary and main secondary outcome measure(s) |
| i | Main safety results | Number of events, SAEs, significant events |

1. Scheduled clinical development

V-1. Synoptic tables of scheduled clinical trials

|  |  |  |
| --- | --- | --- |
| a | Has the management of patients been provided for in the event of toxicity (management of toxicity, modification of doses, including reductions and interruptions) | Yes  No |
| b | Discontinuation criteria (by patient, by cohort, for the study) | Yes  No  *Any divergence must be justified below:* |
| b | Presence of a DSMB | Yes  No  *Any divergence must be justified below:* |

V-2. Conditions of Study “XXX”   
*(Systematically if Application for clinical trial authorisation, only if relevant for Request for scientific advice); (In the event of several studies, complete another section V-3):*

|  |  |  |
| --- | --- | --- |
| a | Study title (and Eudract No.) and study phase |  |
| b | Study objective(s) | * Primary * Secondary |
| c | Study design | In particular, specify whether randomised or non-randomised, open-label or single or double-blind, comparative or non-comparative, parallel groups or otherwise, number of arms, if add-on or not, etc. |
| d | Study population | Total number of subjects  Healthy volunteers or patients (disease)  Main inclusion and exclusion criteria (indication) |
| e | Justification of the population and treatment line relative to the presumed clinical efficacy of the IMP |  |
| f | Dosage | Detail per arm: dose per administration, frequency and route of administration, number of patients, maximum dose |
| g | Outcome measures | Primary outcome measure(s)  Secondary outcome measure(s)  Exploratory outcome measure(s) |

1. Rationale for request for scientific advice (only for a request for scientific advice)

|  |  |
| --- | --- |
| Existence of relevant guidelines | Yes   No  If yes, cite |
| Deviation planned from current Guidelines | Yes   No  List planned deviations (justification will be detailed in the questions asked) |
| Rationale for request for scientific advice | Input expected from the ANSM: nature, area of expertise,  Justification of need |

1. Questions – Responses

|  |
| --- |
| Question 1 |
|  |
| Applicant’s position |
|  |

|  |  |  |
| --- | --- | --- |
| **I hereby certify that the information provided in this document is accurate** | | |
| **Signed on:** | **Signatory’s surname and first name** |  |
| **Signature** | |